Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

M Rieken; L A Kluth; E Xylinas; C Seitz; H Fajkovic; P I Karakiewicz; Y Lotan; A Briganti; W Loidl; T Faison; J J Crivelli; D S Scherr; A Bachmann; A K Tewari; A Kautzky-Willer; K Pummer; S F Shariat

doi:10.1038/pcan.2013.31

Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

Standard

Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. / Rieken, M; Kluth, L A; Xylinas, E; Seitz, C; Fajkovic, H; Karakiewicz, P I; Lotan, Y; Briganti, A; Loidl, W; Faison, T; Crivelli, J J; Scherr, D S; Bachmann, A; Tewari, A K; Kautzky-Willer, A; Pummer, K; Shariat, S F.

in: PROSTATE CANCER P D, Jahrgang 16, Nr. 4, 01.12.2013, S. 367-71.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rieken, M, Kluth, LA, Xylinas, E, Seitz, C, Fajkovic, H, Karakiewicz, PI, Lotan, Y, Briganti, A, Loidl, W, Faison, T, Crivelli, JJ, Scherr, DS, Bachmann, A, Tewari, AK, Kautzky-Willer, A, Pummer, K & Shariat, SF 2013, 'Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy', PROSTATE CANCER P D, Jg. 16, Nr. 4, S. 367-71. https://doi.org/10.1038/pcan.2013.31

APA

Rieken, M., Kluth, L. A., Xylinas, E., Seitz, C., Fajkovic, H., Karakiewicz, P. I., Lotan, Y., Briganti, A., Loidl, W., Faison, T., Crivelli, J. J., Scherr, D. S., Bachmann, A., Tewari, A. K., Kautzky-Willer, A., Pummer, K., & Shariat, S. F. (2013). Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. PROSTATE CANCER P D, 16(4), 367-71. https://doi.org/10.1038/pcan.2013.31

Vancouver

Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PI et al. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. PROSTATE CANCER P D. 2013 Dez 1;16(4):367-71. https://doi.org/10.1038/pcan.2013.31

Bibtex

@article{c69dd2799ea046c58b5c8fa4113c9594,

title = "Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy",

abstract = "BACKGROUND: The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.METHODS: We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni- and multivariable cox regression models addressed the association of statin use with BCR.RESULTS: Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values 0.05). Within a median follow-up of 25 months (interquartile range: 8-42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82%±1 for patients without statin use and 84±1% for patients using statins (P=0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76-1.03, P=0.10) after adjusting for the effects of standard clinicopathologic features.CONCLUSIONS: In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR.",

keywords = "Aged, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Neoplasm Recurrence, Local, Proportional Hazards Models, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Retrospective Studies",

author = "M Rieken and Kluth, {L A} and E Xylinas and C Seitz and H Fajkovic and Karakiewicz, {P I} and Y Lotan and A Briganti and W Loidl and T Faison and Crivelli, {J J} and Scherr, {D S} and A Bachmann and Tewari, {A K} and A Kautzky-Willer and K Pummer and Shariat, {S F}",

year = "2013",

month = dec,

day = "1",

doi = "10.1038/pcan.2013.31",

language = "English",

volume = "16",

pages = "367--71",

journal = "PROSTATE CANCER P D",

issn = "1365-7852",

publisher = "NATURE PUBLISHING GROUP",

number = "4",

}

RIS

TY - JOUR

T1 - Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

AU - Rieken, M

AU - Kluth, L A

AU - Xylinas, E

AU - Seitz, C

AU - Fajkovic, H

AU - Karakiewicz, P I

AU - Lotan, Y

AU - Briganti, A

AU - Loidl, W

AU - Faison, T

AU - Crivelli, J J

AU - Scherr, D S

AU - Bachmann, A

AU - Tewari, A K

AU - Kautzky-Willer, A

AU - Pummer, K

AU - Shariat, S F

PY - 2013/12/1

Y1 - 2013/12/1

N2 - BACKGROUND: The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.METHODS: We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni- and multivariable cox regression models addressed the association of statin use with BCR.RESULTS: Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values 0.05). Within a median follow-up of 25 months (interquartile range: 8-42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82%±1 for patients without statin use and 84±1% for patients using statins (P=0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76-1.03, P=0.10) after adjusting for the effects of standard clinicopathologic features.CONCLUSIONS: In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR.

AB - BACKGROUND: The impact of statin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.METHODS: We retrospectively evaluated 6842 patients who underwent RP for clinically localized prostate cancer (PC) between 2000 and 2011. Uni- and multivariable cox regression models addressed the association of statin use with BCR.RESULTS: Overall, 2275 (33.3%) patients used statins. Statin users were older and had a higher rate of positive surgical margins than patients not using statins (P-values 0.05). Within a median follow-up of 25 months (interquartile range: 8-42 months), 778 (11.4%) patients experienced BCR. Actuarial estimate 5-years BCR-free survival was 82%±1 for patients without statin use and 84±1% for patients using statins (P=0.05); statin use was not associated with BCR (hazard ratio: 0.88, 95% confidence interval: 0.76-1.03, P=0.10) after adjusting for the effects of standard clinicopathologic features.CONCLUSIONS: In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR.

KW - Aged

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Proportional Hazards Models

KW - Prostate-Specific Antigen

KW - Prostatectomy

KW - Prostatic Neoplasms

KW - Retrospective Studies

U2 - 10.1038/pcan.2013.31

DO - 10.1038/pcan.2013.31

M3 - SCORING: Journal article

C2 - 23999669

VL - 16

SP - 367

EP - 371

JO - PROSTATE CANCER P D

JF - PROSTATE CANCER P D

SN - 1365-7852

IS - 4

ER -